Another study showed that Bcl-2 expression correlated very well with the sensitivity of the BCL-2 inhibitor venetoclax in various diffuse large B-cell lymphoma (DLBCL) cell lines [42]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.